Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes

Comparison between glimepiride and metformin

G. Derosa, I. Franzetti, G. Gadaleta, L. Ciccarelli, R. Fogari

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Patients with Type 2 diabetes (T2DM) are at high risk of morbidity and mortality from cardiovascular complications, and hypoglycaemia increases this risk. Furthermore, other metabolic parameters exacerbate cardiovascular risk in these patients. The aim of the study was to compare the metabolic effects of glimepiride and metformin in patients with T2DM. We evaluated 164 patients with T2DM (80 males, 84 females) in a multicentre, randomised, controlled, open, parallel group study comparing glimepiride with metformin. Eighty-one patients (aged 56±10 yr) received glimepiride (3±1 mg/d); 83 patients (aged 58±9 yr) received metformin (2500±500 mg/d). Patients had been diagnosed for ≤6 months; they were non-smokers; had no hypertension or coronary heart disease; were not taking hypolipidaemic drugs, diuretics, β-blockers or thyroxin; and had normal renal function. Metabolic parameters were measured after 6 and 12 months of treatment. Glimepiride significantly lowered lipoprotein(a) [Lp(a)] and homocysteine levels (HCT) at 6 and 12 months. Both glimepiride and metformin lowered plasminogen activator inhibitor Type 1 (PAI-1) at 12 months and significantly improved levels of glycosylated haemoglobin, fasting plasma glucose and postprandial plasma glucose after 6 and 12 months. Metformin significantly lowered fasting plasma insulin and postprandial plasma insulin. Glimepiride and metformin also reduced levels of other metabolic parameters in patients with T2DM. In particular, glimepiride significantly reduced HCT, Lp(a), and PAI-1 levels, important metabolic risk factors for atherosclerotic vascular disease. These reductions may be owing to improved glucose metabolism, but it cannot be excluded that these drugs have a direct effect on additional metabolic parameters.

Original languageEnglish
Pages (from-to)143-150
Number of pages8
JournalDiabetes, Nutrition and Metabolism - Clinical and Experimental
Volume17
Issue number3
Publication statusPublished - Jun 2004

Fingerprint

glimepiride
hypoglycemic agents
metformin
Metformin
Hypoglycemic Agents
noninsulin-dependent diabetes mellitus
Type 2 Diabetes Mellitus
mouth
Lipoprotein(a)
homocysteine
Plasminogen Activator Inhibitor 1
Homocysteine
Glucose
lipoproteins
glucose
fasting
Fasting
insulin
Insulin
Hypolipidemic Agents

Keywords

  • Glimepiride
  • Homocysteine
  • Lipoprotein(a)
  • Metformin
  • Type 2 diabetes

ASJC Scopus subject areas

  • Food Science
  • Endocrinology
  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes : Comparison between glimepiride and metformin. / Derosa, G.; Franzetti, I.; Gadaleta, G.; Ciccarelli, L.; Fogari, R.

In: Diabetes, Nutrition and Metabolism - Clinical and Experimental, Vol. 17, No. 3, 06.2004, p. 143-150.

Research output: Contribution to journalArticle

@article{365a3e0fe7e749568e2a9799bdcfb328,
title = "Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: Comparison between glimepiride and metformin",
abstract = "Patients with Type 2 diabetes (T2DM) are at high risk of morbidity and mortality from cardiovascular complications, and hypoglycaemia increases this risk. Furthermore, other metabolic parameters exacerbate cardiovascular risk in these patients. The aim of the study was to compare the metabolic effects of glimepiride and metformin in patients with T2DM. We evaluated 164 patients with T2DM (80 males, 84 females) in a multicentre, randomised, controlled, open, parallel group study comparing glimepiride with metformin. Eighty-one patients (aged 56±10 yr) received glimepiride (3±1 mg/d); 83 patients (aged 58±9 yr) received metformin (2500±500 mg/d). Patients had been diagnosed for ≤6 months; they were non-smokers; had no hypertension or coronary heart disease; were not taking hypolipidaemic drugs, diuretics, β-blockers or thyroxin; and had normal renal function. Metabolic parameters were measured after 6 and 12 months of treatment. Glimepiride significantly lowered lipoprotein(a) [Lp(a)] and homocysteine levels (HCT) at 6 and 12 months. Both glimepiride and metformin lowered plasminogen activator inhibitor Type 1 (PAI-1) at 12 months and significantly improved levels of glycosylated haemoglobin, fasting plasma glucose and postprandial plasma glucose after 6 and 12 months. Metformin significantly lowered fasting plasma insulin and postprandial plasma insulin. Glimepiride and metformin also reduced levels of other metabolic parameters in patients with T2DM. In particular, glimepiride significantly reduced HCT, Lp(a), and PAI-1 levels, important metabolic risk factors for atherosclerotic vascular disease. These reductions may be owing to improved glucose metabolism, but it cannot be excluded that these drugs have a direct effect on additional metabolic parameters.",
keywords = "Glimepiride, Homocysteine, Lipoprotein(a), Metformin, Type 2 diabetes",
author = "G. Derosa and I. Franzetti and G. Gadaleta and L. Ciccarelli and R. Fogari",
year = "2004",
month = "6",
language = "English",
volume = "17",
pages = "143--150",
journal = "Diabetes, Nutrition and Metabolism - Clinical and Experimental",
issn = "0394-3402",
publisher = "Editrice Kurtis s.r.l.",
number = "3",

}

TY - JOUR

T1 - Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes

T2 - Comparison between glimepiride and metformin

AU - Derosa, G.

AU - Franzetti, I.

AU - Gadaleta, G.

AU - Ciccarelli, L.

AU - Fogari, R.

PY - 2004/6

Y1 - 2004/6

N2 - Patients with Type 2 diabetes (T2DM) are at high risk of morbidity and mortality from cardiovascular complications, and hypoglycaemia increases this risk. Furthermore, other metabolic parameters exacerbate cardiovascular risk in these patients. The aim of the study was to compare the metabolic effects of glimepiride and metformin in patients with T2DM. We evaluated 164 patients with T2DM (80 males, 84 females) in a multicentre, randomised, controlled, open, parallel group study comparing glimepiride with metformin. Eighty-one patients (aged 56±10 yr) received glimepiride (3±1 mg/d); 83 patients (aged 58±9 yr) received metformin (2500±500 mg/d). Patients had been diagnosed for ≤6 months; they were non-smokers; had no hypertension or coronary heart disease; were not taking hypolipidaemic drugs, diuretics, β-blockers or thyroxin; and had normal renal function. Metabolic parameters were measured after 6 and 12 months of treatment. Glimepiride significantly lowered lipoprotein(a) [Lp(a)] and homocysteine levels (HCT) at 6 and 12 months. Both glimepiride and metformin lowered plasminogen activator inhibitor Type 1 (PAI-1) at 12 months and significantly improved levels of glycosylated haemoglobin, fasting plasma glucose and postprandial plasma glucose after 6 and 12 months. Metformin significantly lowered fasting plasma insulin and postprandial plasma insulin. Glimepiride and metformin also reduced levels of other metabolic parameters in patients with T2DM. In particular, glimepiride significantly reduced HCT, Lp(a), and PAI-1 levels, important metabolic risk factors for atherosclerotic vascular disease. These reductions may be owing to improved glucose metabolism, but it cannot be excluded that these drugs have a direct effect on additional metabolic parameters.

AB - Patients with Type 2 diabetes (T2DM) are at high risk of morbidity and mortality from cardiovascular complications, and hypoglycaemia increases this risk. Furthermore, other metabolic parameters exacerbate cardiovascular risk in these patients. The aim of the study was to compare the metabolic effects of glimepiride and metformin in patients with T2DM. We evaluated 164 patients with T2DM (80 males, 84 females) in a multicentre, randomised, controlled, open, parallel group study comparing glimepiride with metformin. Eighty-one patients (aged 56±10 yr) received glimepiride (3±1 mg/d); 83 patients (aged 58±9 yr) received metformin (2500±500 mg/d). Patients had been diagnosed for ≤6 months; they were non-smokers; had no hypertension or coronary heart disease; were not taking hypolipidaemic drugs, diuretics, β-blockers or thyroxin; and had normal renal function. Metabolic parameters were measured after 6 and 12 months of treatment. Glimepiride significantly lowered lipoprotein(a) [Lp(a)] and homocysteine levels (HCT) at 6 and 12 months. Both glimepiride and metformin lowered plasminogen activator inhibitor Type 1 (PAI-1) at 12 months and significantly improved levels of glycosylated haemoglobin, fasting plasma glucose and postprandial plasma glucose after 6 and 12 months. Metformin significantly lowered fasting plasma insulin and postprandial plasma insulin. Glimepiride and metformin also reduced levels of other metabolic parameters in patients with T2DM. In particular, glimepiride significantly reduced HCT, Lp(a), and PAI-1 levels, important metabolic risk factors for atherosclerotic vascular disease. These reductions may be owing to improved glucose metabolism, but it cannot be excluded that these drugs have a direct effect on additional metabolic parameters.

KW - Glimepiride

KW - Homocysteine

KW - Lipoprotein(a)

KW - Metformin

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=4344561397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344561397&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 143

EP - 150

JO - Diabetes, Nutrition and Metabolism - Clinical and Experimental

JF - Diabetes, Nutrition and Metabolism - Clinical and Experimental

SN - 0394-3402

IS - 3

ER -